Hookle, a Finland-based tech company, is advancing sustainable growth for over 30 million U.S. micro-businesses with its AI-powered social media marketing app. By simplifying digital marketing, Hookle ...
1don MSN
Industry leaders in health and science converged in downtown Raleigh Thursday to highlight the area’s latest advancements in ...
TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $275.00. The company’s shares closed yesterday at $164.89. According to TipRanks ...
Baird raised the firm’s price target on Biogen (BIIB) to $300 from $294 and keeps an Outperform rating on the shares. The firm said Biogen partner Eisai’s request for the EMA’s CHMP to reexamine the ...
A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...
Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session for ...
In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of ...
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback